|
Age (y) |
Sex |
Dose order |
Injection site |
LN side |
Symptoms |
Vaccination to lymphadenopathy
interval* (d) |
Lymphadenopathy to referral
interval (d) |
Referral to USS interval (d) |
Outcome+
|
Time for outcome (w) |
1 |
54 |
F |
1st |
Left |
Ipsilateral |
Tenderness |
11 |
16 |
9 |
FR |
8 |
2 |
27 |
F |
1st |
Left |
Ipsilateral |
Tenderness |
5 |
7 |
3 |
FR |
3 |
3 |
60 |
F |
1st |
Left |
Ipsilateral |
None |
3 |
2 |
6 |
FR |
2 |
4 |
40 |
M |
1st |
Left |
Ipsilateral |
None |
1 |
44 |
8 |
ND |
ND |
5 |
76 |
F |
1st |
Left |
Ipsilateral |
None |
4 |
17 |
7 |
PR |
5 |
6 |
41 |
F |
1st |
Left |
Ipsilateral |
None |
7 |
26 |
10 |
FR |
2 |
7 |
73 |
F |
1st |
Left |
Ipsilateral |
Tenderness |
7 |
7 |
5 |
FR |
3 |
8 |
55 |
F |
1st |
Left |
Ipsilateral |
None |
14 |
41 |
12 |
PR |
12 |
9 |
57 |
F |
1st |
Left |
Ipsilateral |
None |
2 |
37 |
12 |
PR |
11 |
10 |
56 |
F |
2nd |
Left |
Ipsilateral |
Tenderness |
1 |
45 |
12 |
PR |
8 |
11 |
81 |
F |
1st |
Right |
Ipsilateral |
Tenderness |
10 |
38 |
10 |
PR |
6 |
12 |
34 |
M |
1st |
Left |
Ipsilateral |
None |
2 |
3 |
4 |
FR |
3 |
13 |
58 |
F |
1st |
Left |
Ipsilateral |
None |
2 |
2 |
7 |
FR |
1 |